Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 13, 2020 16:45 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Reports Fourth Quarter 2019 Financial Results

Net revenue for ELZONRIS® was $11.8 million for the fourth quarterConference call and live webcast scheduled for Monday, March 16th, at 8:00 AM ET NEW YORK, March 13, 2020 (GLOBE NEWSWIRE) --...
March 11, 2020 16:05 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Host Conference Call on Fourth Quarter 2019 Financial Results on March 16, 2020

NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
February 26, 2020 07:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at the Cowen 40th Annual Health Care Conference

NEW YORK, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
January 13, 2020 16:15 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS® (tagraxofusp) and Highlights Commercial and Clinical Growth Drivers

NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
January 08, 2020 16:15 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
December 10, 2019 08:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Recaps ELZONRIS Clinical Data Presentations in Patients with Myelofibrosis (oral presentation) and Multiple Myeloma at the 61st American Society of Hematology (ASH) Annual Meeting

NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
December 06, 2019 18:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Names Robert M. Francomano Chief Commercial Officer

NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
December 06, 2019 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Highlights Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting

NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
November 29, 2019 13:05 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at Piper Jaffray’s 31st Annual Healthcare Conference

NEW YORK, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
November 07, 2019 16:57 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Reports Third Quarter 2019 Financial Results

Net revenue for ELZONRIS® was $13.3 million for the third quarterNew patient starts estimated to have increased greater than 20% from last quarterConference call and live webcast scheduled for...